Key facts
- This page summarizes Jolanda Howe's Form 4 filing for Mirum Pharmaceuticals, Inc. (MIRM).
- 8 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 18 Mar 2025, 21:30.
Jolanda Howe - 15 Mar 2025 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)
- Reporting relationship
- SVP, GLOBAL CONTROLLER
- Issuer ticker
- MIRM
- Reported as of
- 15 Mar 2025
- Net transaction value
- -$2,399,237
- SEC form
- 4
- Accepted by SEC
- 18 Mar 2025, 21:30:09 UTC
- Prior SEC filing
- 04 Feb 2025
- Next SEC filing
- 19 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Judit Ryvkin, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jolanda Howe filed Form 4 for Mirum Pharmaceuticals, Inc. (MIRM) on 18 Mar 2025.
Change
- Previous filing in this sequence was filed on 04 Feb 2025.
- Current net transaction value: -$2,399,237.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MIRM
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +5,315
- Change %
- +126%
- Price
- Shares after
- 9,547
- Date
- 15 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
MIRM
transaction
Common Stock
Sale
- Transaction value
- $128,221
- Shares
- -2,900
- Change %
- -30%
- Price
- $44.21
- Shares after
- 6,647
- Date
- 17 Mar 2025
- Ownership
- Direct
- Footnotes
- F2
MIRM
transaction
Common Stock
Options Exercise
- Transaction value
- $155,526
- Shares
- +52,900
- Change %
- +796%
- Price
- $2.94
- Shares after
- 59,547
- Date
- 17 Mar 2025
- Ownership
- Direct
MIRM
transaction
Common Stock
Sale
- Transaction value
- $2,221,626
- Shares
- -50,111
- Change %
- -84%
- Price
- $44.33
- Shares after
- 9,436
- Date
- 17 Mar 2025
- Ownership
- Direct
- Footnotes
- F3, F4
MIRM
transaction
Common Stock
Sale
- Transaction value
- $124,802
- Shares
- -2,789
- Change %
- -30%
- Price
- $44.75
- Shares after
- 6,647
- Date
- 17 Mar 2025
- Ownership
- Direct
- Footnotes
- F3, F5
MIRM
transaction
Common Stock
Sale
- Transaction value
- $80,113
- Shares
- -1,806
- Change %
- -27%
- Price
- $44.36
- Shares after
- 4,841
- Date
- 17 Mar 2025
- Ownership
- Direct
- Footnotes
- F3, F6
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MIRM
transaction
Derivative
Performance Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -5,315
- Change %
- -67%
- Price
- $0.000000
- Shares after
- 2,658
- Date
- 15 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,315
- Exercise price
- Footnotes
- F1, F7
MIRM
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -52,900
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 17 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 52,900
- Exercise price
- $2.94
- Footnotes
- F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 8 footnotes
Footnote F1
Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Footnote F2
Shares sold to cover tax withholding obligations associated with the vesting of the performance restricted stock units.
Footnote F3
Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 16, 2024.
Footnote F4
The weighted average sale price for the transaction reported was $44.33410, and the range of prices were between $43.695 and $44.695. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
Footnote F5
The weighted average sale price for the transaction reported was $44.74811, and the range of prices were between $44.70 and $44.84. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
Footnote F6
The weighted average sale price for the transaction reported was $44.35923, and the range of prices were between $43.81 and $44.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
Footnote F7
The shares vest as follows: 2/3 of the shares vest on March 15, 2025 and 1/3 of the shares vest on March 15, 2026.
Footnote F8
The stock option is fully vested.